Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models

详细信息    查看全文

• 作者：Neil Mathias ; Yan Xu ; Balvinder Vig ; Umesh Kestur ; Amy Saari…
• 关键词：biorelevant dissolution ; dog food effect model ; food effect ; in vitro ; in vivo relationship
• 刊名：The AAPS Journal
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：17
• 期：4
• 页码：988-998
• 全文大小：445 KB
• 参考文献：1.US Food and Drug Administration. Food-effect bioavailability and fed bioequivalence studies: guidance for industry. http://?www.?fda.?gov/?downloads/?regulatoryinform?ation/?guidances/?ucm126833.?pdf . 2002.
  2.Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet. 1999;36:233-4.PubMed View Article
  3.Charman WN, Porter C, Methani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of pH and lipids. J Pharm Sci. 1997;86:269-2.PubMed View Article
  4.Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, et al. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:342-6.PubMed View Article
  5.Sj?gren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, et al. In vivo methods for drug absorption—comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci. 2014;57:99-51.PubMed View Article
  6.Sugano K, Kataoka M, Mathews C, Yamashita S. Prediction of food effect by bile micelles on oral drug absorption considering free fraction in the intestinal fluid. Eur J Pharm Sci. 2010;40:118-4.PubMed View Article
  7.Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K, et al. Predicting effect of food on the extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24:1118-0.PubMed View Article
  8.Singh BN. A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio and partition coefficient (Log P) for orally active drugs administered as immediate release formulations. Drug Dev Res. 2005;65:55-5.View Article
  9.Parrott N, Lukava V, Fraczkiewicz G, Bolger MB. Predicting pharmacokinetics of drug using physiologically based modeling: application to food effects. AAPS J. 2009;11:45-3.PubMed Central PubMed View Article
  10.Heimbach T, Binfeng X, Liu T, He H. Case studies for practical food effect assessment across BCS/BDDCS Class compounds using in silico, in vitro and preclinical in vivo data. AAPS J. 2012;15:143-8.PubMed Central PubMed View Article
  11.Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:300-1.PubMed View Article
  12.Dressman JB, Reppas C. In vitro-in vivo correlation for lipophilic, poorly soluble drugs. Eur J Pharm Sci. 2000;11:S73-0.PubMed View Article
  13.Katoaka M, Itsubata S, Masaoka Y, Sakuma S, Yamashita S. In vitro dissolution/permeability system to predict the oral absorption of poorly water soluble drugs: effect of food and dose strength on it. Biol Pharm Bull. 2011;34:401-.View Article
  14.Lentz K, Quitko M, Morgan DG, Grace JE, Gleason C, Marathe PH. Development and validation of a preclinical food effect model. J Pharm Sci. 2007;96:459-2.PubMed View Article
  15.Zane P, Guo Z, MacGerorge D, Vicat P, Ollier C. Use of the pentagastrin dog model to explore the food effects on formulations in early drug development. Eur J Pharm Sci. 2014;57:207-3.PubMed View Article
  16.Balimane P, Han YH, Chong S. Current industrial practices in assessing permeability and P-glycoprotein interactions. AAPS J. 2006;8:E1-3.PubMed Central PubMed View Article
  17.Lennernas H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol. 1997;49:627-8.PubMed View Article
  18.Benet LZ, Brocatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13:519-7.PubMed Central PubMed View Article
  19.Ku S. Use of the biopharmaceutical classification system in early drug development. AAPS J. 2008;10:208-2.PubMed Central PubMed View Article
  20.Galia E, Nicolaides E, H?rter D, L?benberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15:698-05.PubMed View Article
  21.Sagawa K, Fasheng LL, Liese R, Sutton S. Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. J Pharm Sci. 2009;98:2494-00.PubMed View Article
  22.Dressman JB. Comparison of canine and human gastrointestinal physiologies. Pharm Res. 1986;3:123-1.PubMed View Article
  23.Braganza JM, Herman K, Hine P, Kay G. The effect of pentagastrin on peptic secretion in man. J Physiol. 1979;289:9-6.PubMed Central PubMed View Article
  24.Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999;37:213-5.PubMed View Article
  25.Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification s
• 作者单位：Neil Mathias (1)
  Yan Xu (1)
  Balvinder Vig (1)
  Umesh Kestur (1)
  Amy Saari (1)
  John Crison (1)
  Divyakant Desai (1)
  Aditya Vanarase (1)
  Munir Hussain (1)
  
  1. Drug Product Science & Technology, Bristol-Myers Squibb Co., New Brunswick, New Jersey, 08903, USA
  
• 刊物主题：Pharmacology/Toxicology; Biochemistry, general; Biotechnology; Pharmacy;
• 出版者：Springer US
• ISSN：1550-7416

文摘

In vitro and in vivo experimental models are frequently used to assess a new chemical entity’s (NCE) biopharmaceutical performance risk for food effect (FE) in humans. Their ability to predict human FE hinges on replicating key features of clinical FE studies and building an in vitro-in vivo relationship (IVIVR). In this study, 22 compounds that span a wide range of physicochemical properties, Biopharmaceutics Classification System (BCS) classes, and food sensitivity were evaluated for biorelevant dissolution in fasted- and fed-state intestinal media and the dog fed/fasted-state pharmacokinetic model. Using the area under the curve (AUC) as a performance measure, the ratio of the fed-to-fasted AUC (FE ratio) was used to correlate each experimental model to FE ratio in humans. A linear correlation was observed for the in vitro dissolution-human IVIVR (R 2--.66, % mean square error 20.7%). Similarly, the dog FE ratio correlated linearly with the FE ratio in humans (R 2--.74, % mean square error 16.25%) for 15 compounds. Data points near the correlation line indicate dissolution-driven mechanism for food effect, while deviations from the correlation line shed light on unique mechanisms that can come into play such as GI physiology or unusual physicochemical properties. In summary, fed/fasted dissolution studies and dog PK studies show a reasonable correlation to human FE, hence are useful tools to flag high-risk NCEs entering clinical development. Combining kinetic dissolution, dog FE model and in silico modeling one can study FE mechanism and formulation strategies to mitigate the FE risk.